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T cells recognize antigen (Ag) t in association with MHC determinants (1). In
most cases, helper/inducer T cells recognizeAgin the context ofclass II MHC mol-
ecules, while cytotoxic/suppressor cells recognize Ag in the context ofclass I MHC
molecules. Althoughthisconcept ofMHC restriction is wellestablished, the mecha-
nisms underlying its acquisitionstillremain unclear. Toelucidatethispoint, numerous
studies have been performedin murine lymphohaematopoietic chimeras (1-5). Ex-
perimentsin which bonemarroworfetal livercellsareinjectedinto irradiated semi-
allogeneic or fully allogeneic hosts have indicated thatthe chimeric T cells ofdonor
origin are restricted in their capacity to recognize antigen by class II MHC mole-
culesoftherecipient in whichtheymature. Based onthese observations, it has been
suggestedthat MHC restrictionisacquiredduring T cellontogeny and is not genet-
ically determined. The thymus appears to play the major role in the determination
of this restriction (2, 6).
In contrast to animal models, studies on the development ofMHC restriction by
human T cells are very limited. Thus far, the majority of the results reported in
the literature have been obtained in patients suffering from severe combined im-
munodeficiency (SLID) transplanted with HLAhaploidentical bone marrow(7, 8).
In this situation, contribution ofthe shared HLA haplotype to the development of
T cell repertoire could not be ruled out. Another major drawback until now was
that the in vitroexperiments were not performed at the clonal level, therefore, the
possibility ofcontamination by donor T cells in the host population and vice versa
could not be excluded (7, 8).
Recently, we described patients suffering from SLID who were immunologically
reconstituted after complete allogeneic fetal liverand thymus transplantations (FLTT)
(9, 10). A more detailed study carried out on one patient, who now has a follow-up
of11 yr, showed that 7 yraftertransplantation allTcells ofthe patientwere ofdonor
origin, whereas the B lymphocytes and monocytes were ofhost origin (10, 11). De-
spite this complete HLA mismatch between the fetus-derived T cells and the recip-
ient cells, the patient had normal immune responses against pathogenic microor-
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1 Abbreviations used in this paper . Ab, antibody; Ag, antigen; FLTT, fetal liver and thymus transplan-
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ganisms and thymus-dependent antigens (9, 11). Therefore, this patient represents
a unique model to study the MHC restriction of Ag recognition by T cells. For this
reason, tetanus toxin (TT)-specific T cell clones from the patient's PBL were estab-
lished. In the present paper, we show that T cell clones ofdonor origin could specifically
recognize TT in the context of recipient MHC resulting in proliferation. To our
knowledge, this is the first demonstration that Ag recognition can occur in the con-
text of"allo"MHC instead of "self" MHC at the clonal level in humans. In addition,
TTspecific T cell clones able to recognize Ag in a non-MHC-restricted manner
have been isolated.
Materials and Methods
Patient.
￿
The patient S.P.S. had a family history of SLID and was brought up in strict
isolation from birth. At the age of 1 and 5 mo, he received FLTT from two different HLA-
incompatible donors who were 13 and 10 wk old (gestational age), respectively. Only after
the second transplant were clinical improvement and progressive immunological reconstitu-
tion observed. The clinical course of the patient before and after transplantations has been
reported previously (9, 10). 2 yr after transplantation, the patient was immunized with TT
by three injections at 1-mo intervals and serum antiTT antibodies (Abs) were detected. The
booster immunizations given in the following years always resulted in increased serum levels
of antiTT Abs. AntiTT Ab production by PBL of the patient has been also demonstrated
in vitro (11). In addition, the patient exhibited a positive delayed hypersensitivity skin reac-
tion to TT.
The patient, who is 11 yr old now, has continued to do well since the transplantation, is
in apparent good health, and is free ofsignificant infections. Despite normal totallymphocyte
counts and normal numbers of CD3' CD2' T cells, he has a persistent inverted
CD4' /CD8' ratio (ranging from 0.56 to 0.78). This inverted ratio is due both to a decrease
in CD4' T cells and to an increase in CD8' T cells.
Preparation of TT-specific T Cell Lines and Establishment of T Cell Clones.
￿
Peripheral blood
of the patient was drawn 2 wk after an in vivo immunization with TT. PBL were isolated
by Ficoll/Hypaque density gradient centrifugation. 106 PBL were resuspended in 1 ml Yssel's
medium (12) supplemented with 1% human AB' serum (heat inactivated, 30 min at 56°C)
and were stimulated with TT (Calbiochem-Behring Corp., LaJolla, CA) at a concentration
of 25 ug/ml. After incubation at 37°C in 5% C02 for 6 d, these T'I=activated cells were
resuspended in medium containing 20 IU rIL-2/ml (kindly provided by Dr. R. Kastelein,
DNAXResearch Institute, Palo Alto, CA). 12 d after the onset of the culture, the cells were
cloned by limiting dilution at a concentration of one cell per three wells in 96-well round-
bottomed plates (Titertek, Flow Laboratories, Irvine, Scotland) in the presence of a feeder
cell mixture consisting of 5 x 105 irradiated (4,000 rad) allogeneic PBL per ml, 5 x 104 ir-
radiated (5,000 rad) cells per ml of the patient's EBVtransformed B cell line (SPS), 0.1 ug/ml
purified PHA (Wellcome Diagnostics; Beckenham, UK), and 25 wg/mlTT After 14 d, prolifer-
ating T cell cultures were transferred to 24-well tissue culture plates (Linbro; Flow Laborato-
ries) and restimulated with the feeder cell mixture. The clones were further expanded inmedium
containing rIL-2. 10 d afterthe last stimulation, the clones were screened for their specificity
and functional activities as described below.
Cell Lines,
￿
The EBV cell lines of the patient (SPS), his father (Ul593), and his mother
(UD94) originated from infection of fresh PBL with EBV obtained from the marmoset lym-
phoblastoid cell line B 95=8: All cell lineswere cultured in Yssers medium supplemented with
1 % human AB' serum.
Preparation ofAPC.
￿
The EBV cell lines and fresh PBL used as APC were irradiated at
5,000 and 4,000 rad, respectively, washed, and added to the culture.
In some proliferation experiments EBV cell lines or PBL were preincubated in the pres-
ence of 25 kg/ml of TT in 5% C02 at 37°C. After a period of 16-24 h, Ag-pulsed cells were
washed three times, resuspended in complete medium, and used for Ag presentation.
For treatment of EBV cell lineswith chloroquine (Sigma Chemical Co., St. Louis, MO),RONCAROLO ET AL .
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cells were suspended at 106/ml in Yssel's medium and freshly prepared chloroquine was added
at a final concentration of 0.1 mM 30 min before the addition ofTT. After 5 h, the cells
were washed three times with PBS and fixed with 0.05% glutaraldehyde for 1 min at room
temperature . The reaction was stopped with 0.2 M glycine in PBS. The cells were washed
three times and resuspended in complete medium .
The type I humanT leukemia virus(HTLV1)-transformedTcell clones B21 p19 and 827
p19 were obtained by cocultivating theTTspecific T cell clones B21, which is derived from
the patient, and 827, which is of allogeneic origin, with the HTLV1-secreting cell line C
91/pl (13) . It hasbeen shown recently that these HTLVI-infectedTcell clones have the ability
to present antigen to MHC-restricted Tcells (Yssel,H.,R. de Wall Malefyt,M . Duc Dodon,
D. Blanchard, L. Gazzolo, J . E. De Vries, and H . Spits, submitted for publication) .
HLA Typing .
￿
HLA typing was carried out on the T cell clones and EBVtransformed B
cell lines using a cytotoxicity assay as described previously (14) .
Antigen-induced T Cell Proliferation .
￿
9-12 d after stimulation with feeder cells, the cloned
T cells were washed three times and 2 x 104 of these cells were incubated with 2 x 10 4 ir-
radiated (5,000 rad) APC in the presence or absence of solubleTT at a final dilution of 1 :100
corresponding to 25 pg/ml, or 10 pg/ml of purified protein derivative (PPD ; a kind gift of
Dr. Kreeftenberg, RijksInstuut voor de Volksgezondheid, Bilthoven, Netherlands) in a final
volume of 200 41 Yssel's medium with 10 1o human AB' serum . After 3 d of incubation, 1
gCi [3H]TdR (New England Nuclear, Dreieich, Federal Republic of Germany) was added
to each well . 4 h later, the cells were harvested onto glass fiber strips usingasemi-automated
cell harvester and the amount of incorporated [3H]TdR was assessed by liquid scintillation
counting . The results are expressed as the mean of triplicate cultures t SD. The effect of
mAbs on the proliferative capacity ofT cell clones was determined by adding varied amounts
of mAb at the onset of the cultures .
mAbs .
￿
The anti-CD2 mAb used in this study wasCLBT11 (kindly provided by Dr. R.
Van Lier, Central Laboratory oftheNetherlands RedCross BloodTransfusion Service, Nether-
lands) . The anti-CD4 mAb RIV6 was kindly provided by Dr. Kreeftenberg (Rijks Instuut
voor de Volksgezondheid, Bilthoven, Netherlands) . The anti-CD8 mAb SPVT8 and the anti-
CD3mAbSPVT3b have been describedbefore (15) . ThemAbW6/32, which detectsacommon
determinant on all class I HLA molecules, was obtained from Sera Lab (Crawley Down,
UK). The antibody SPVL3 reacts with a monomorphic determinant on HLA-DQ mole-
cules (15) . ThemAb Q5/13 was a kind gift from Dr. S. Ferrone (Medical College, Valhalla,
NY) anddetectsa determinant common to HLA-DR and HLA-DP molecules (16) . ThemAb
135 detects a determinant on HLA-DR (17) .
Fluorescence Analysis .
￿
10 5 cells were added per well ofa Vbottomed microtiter plate and
washed once with PBS containing 0.02 mM NaN3 and 1% BSA. The cells were then in-
cubated with mAbs for 30 min at 40C. After two washes in PBS/azide/BSA, the cells were
incubated with a 1 :40 dilution of FITC-labeled F(ab')2 fragments of a goat anti-mouse an-
tibody (Bioart, Meudon, France) and incubated for 30 min at 4°C. After three washes, the
cells were transferred to FACS tubes (Becton Dickinson& Co., Oxnard, CA) and analyzed
on a FACS (model 440; Becton Dickinson & Co.) .
Results
HLA Typing ofPBL, Cell Lines, and T Cell Clones.
￿
The HLA typing of parental
PBL and patient's PBL before transplantation is shown in Table I . HLA typing of
the patient's PBL, carried out by conventional cytotoxicity assays during the follow-
up after transplant, revealed the progressive engraftment of cells from the second
donor (HLA-A1,2; C7 ; B8,18; DR3,9) while the cells from the first donor (HLA-
A2,11 ; C4 ; B62,27 ; DR1,8), present at low numbers at the beginning, progressively
became less detectable in peripheral blood. Furthermore, theHLAtyping, performed
7 yr after transplantationon separatedT andBcell populations and monocytes (Table
1) indicated that allthe B lymphocytes and monocytesremained ofhost origin,whereas
the T lymphocytes were donor derived .142
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TABLE I
HLA Typing ofthe Patient andhis Parents
* HLA genotypes of the family.
T HLA phenotype ofthe patient 7 yr afterthetransplantation. HLA typing was
carried out on enriched cell populations.
HLA typing ofthe TTspecific Tcell clones and the EBV cell line obtained from
the patient's PBL (Table II) confirmed the split chimerism. The EBV cell line SPS
has the HLA phenotype ofthe recipient, whereas the T cell clones have the HLA
phenotype ofthetransplanted cells. Asexpected from the resultsobtainedwithPBL,
the T cellclones F1, F9, F15, and F17 have the HLAphenotypeofthe second donor.
Interestingly, Tcellclones F3, F11, F13, and F14havethephenotypeofthe firstdonor,
indicating that, althoughthese cellswere not readilydetectable inconventional HLA
typing tests carried out on fresh PBL, they are present and functional.
ScreeningandCharacterization ofTCellClones.
￿
ScreeningoftheTcellclones showed
that 12of15clones proliferated specifically inresponsetoT'Tprocessedandpresented
by the patient EBV cell line SPS. The majority of these clones were also cytotoxic
forSPS pulsed withTT (not shown). The responseswere specific forTT, sincenone
ofthese Tcell clones could be induced to proliferate or were cytotoxic against SPS
in the absence ofTT In addition, no responsiveness was observed in the presence
ofPPD(not shown). Analysis ofthesurfacemarkersrevealed thatall the TTspecific
cell clones were C132', MY, CD4', CD8" .
TABLE 11
HLA Typing ofPatient's EBV Cell Line and T Cell Clones
Subject HLA locus HLA locus HLA locus HLA locus
A C B DR
Father*
a 1 W4 17 7
b W33 W6 14 4
Mother*
c 3 W2 W47 5
d W26 W4 12 1
Patient*
b W33 W6 14 4
c 3 W2 W47 5
Patientt
T cells donor 1-2 W7 8-18 3-W9
B cells host W33-3 W6 14-W47 4-5
Monocytes host W33-3 14-W47 4-5
Cell lines A C
HLA
B DR DQ
EBV cell line SPS (Recipient) W33-3 W6 14-W47 4-5 W3
T cell clones
F3, F11, F13, and F14 (1° FLTT) 2-11 W4 62-27 1-W8 W1
T cell clones
Fl, F9, F15, and F17 (2° FLTT) 1-2 W7 8-18 3-W9 W3RONCAROLO ET AL.
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Clones F3, F11, F13, and F14, which have the HLA phenotype ofthe first trans-
plant, and clones Fl, F9, F15, and F17, which derived from the second donor, were
selected for further characterization.
MHC Restriction of TT-specific TCell Clones.
￿
To demonstrate that presentation of
TT to the specific Tcell clones could also be mediated by APC present in vivo, we
examinedtheproliferative responsesofT cell clones to TT usingpatient'sandparents'
fresh PBL asAPC. As shown inTable III, all eight Tcell clones recognized antigen
presented bythe freshPBLofthe patient, which containboth Bcells and monocytes
ofrecipientorigin. In addition, T cellclones F9, F15, andF17 recognizeTTpresented
by PBL ofthe mother, while T cell clones Fll and F13 recognize TT presented by
PBL of the father. These data indicate that both the TTspecific Tcell clones F9,
F15, and F17, derived from theT cells ofthe second transplant, and the Tcell clones
Fll and F13, derived from thefirsttransplant, are restricted by theHLAdeterminants
of the recipient's fresh PBL.
Surprisingly, T cell clones Fl, F3, and F14 proliferated to TT when both PBL
of the father or the mother (which have no serologically defined HLA antigens in
common in the haplotype inherited by the patient) were used as APC. This sug-
gested that these clones either recognize TT in a non-MHC-restricted manner or
recognize TT in the context of an unknown HLA epitope shared by the parents.
Analysis ofRecipient MHC-restricted T Cell Clones.
￿
To further analyze the restric-
tion element ofTcell clones F9, F11, F13, F15, and F17, we examined the prolifera-
tive responses to TT using the parental EBV cell lines and a limited panel of al-
logeneic EBV cell lines as APC.
In Table IV, it is shown that T cell clones F9, F15, and F17 (which express HLA-
DR3,9) recognized TT processedand presentedby themother's EBVcell line UD94
and by the allogeneic EBV cell line 11.3, which share HLA-DR5 antigen with the
patient. The T cell clones F9, F15, and F17 failed to respond to TT plus the father's
EBV cell line UD93 and JY, which share HLA-DR4 antigen with the patient, or
the allogeneic EBV cellline NOB. In addition, when TTwas presentedbythe EBV
TABLE III
Proliferative Response of T Cell Clones to TT Presented by Fresh PBL
* In all cases, the SD was <10% of the total cpm and the proliferation of T cells to TT in
the absence of APC was <0.3 x 103 cpm .
[3H]TdR incorporation.
S Significant [3H]TdR incorporation is underscored.
APC Ag F9 Fll
Responder T Cell Clones*
F13 F15 F17 Fl F3 F14
cpm x 10-3
PBL
Patient - 01 0 0 0.3 0.6 0.8 0 0.1
Patient TT 6.5S 17.0 37.9 11 .5 31 .4 28.2 10.4 3 .9
Mother - 0 0 0.4 0.5 0.1 0.1 0.1 0.1
Mother TT 5 .8 1.2 1 .4 11 .2 28.6 18.9 7.1 2 .8
Father - 0 0.1 0.4 0.2 0.4 0.2 0.1 0.1
Father TT 0.3 14.5 28.8 1 .7 1 .1 13.5 7.4 3 .52144
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TABLE IV
Proliferative Response of HLA Class H-restricted T Cell Clones to TT
Presented by a Panel of EBV Cell Lines
' In all cases, [3H]TdR incorporation of T cells in the presence of TT alone was <0.4 x 103 cpm and the
SD was <10% .
1 [3H]TdR incorporation.
5 Significant [3H]TdR incorporation is underscored.
cell lines HSY, QBL, and AVL, which share HLA-DR3 with the T cell clones, no
proliferative responses were detected. The other two T cell clones, F11 and F13 (HLA-
DR1,8), recognized TT presented by the EBV cell line UD93 derived from the fa-
ther and byJY, which expresses HLA-DR4. Taken together these results suggest
that HLA-DR5 is the.element ofrestriction ofT cell clones F9, F15, and F17, while
T cell clones Fll and F13 are restricted by HLA-DR4.
To confirm these data, blocking studies with mAbs directed against class I and
II HLA antigens were performed. The proliferation ofall five CD4+ T cell clones,
F9, F11, F13, F15, and F17, in response to TT presented by the recipient EBV cell
line SPS, was strongly blockedby the anti-HLA-DR mAb 135 andby theanti-HLA-
DR, DP mAb Q5/13. In contrast, mAbs against HLA-DQ(SPVL3) and HLA-A,
-B, and -C (W6/32) were ineffective (Table V). The inhibition by mAbs 135 and
Q5/13 was specific since these mAbs did not affect the proliferative responses and
the cytotoxic activity ofCD8+ HLA class I-specific T cell clones obtained from the
patient (18). In addition, as will be shown in Table VIII, the response ofthe MHC-
nonrestricted TTspecific T cell clone F3 was not blocked by mAbs Q5/13 and 135.
These data demonstrate that the T cell clones F11 and F13, derived from the first
transplant (HLA-DR1,8) and the T cell clones F9, F15, and F17 derived from the
APC
HLA-DR
phenotype Ag
-
F9
Responder
Fll
T cell clones'
1713 F15 F17
cbm x 70 -3
SPS 4,5 - 0.31 0.2 0.4 0.2 0.2
(Patient) TT 26.65 33.3 43 .8 47.4 163.7
UD94 1,5 - 0.1 1 .4 0.5 0.6 0.5
(Mother) TT 11 .0 1 .3 0.8 5.6 5 .4
UD93 7,4 - 0.1 0.5 0.4 0.5 1 .6
(Father) TT 0.3 30.1 35.9 2.3 3 .0
NOB 2 - 0.1 0.3 0.1 0.6 0.2
TT 0.6 0.9 1 .5 1 .5 0.4
JY 6,4 - 0.8 0.1 0.1 0.1 0.4
TT 0.3 16.4 6.9 0.6 0.9
11 .3 3,5 - 0.1 0.5 0.1 0.3 0.1
TT 109.0 0.9 0.4 13.7 222.5
HSY 3,7 - 0.1 0.1 0.1 0.1 0.6
TT 0.4 0.1 0.4 0.1 0,5
QBL 3 - 0.1 0 0 0 0
TT 0.1 0 0 0.3 0
AVL 3 - 0.3 0 0 0 0
TT 0.7 0 0 0.3 0.1RONCAROLO ET AL.
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TABLE V
The Effect ofAnti-HLA mAbs on the Proliferative Response of
TT-specific HLA-restricted T Cell Clones
F17
0
0
97
97
26.4 f 6.911 33.3 t 2.211 53.8 t 9.211 29.5 t 2 .411 248.3 ± 2.711
The host-derived EBV cell line SPS was used as APC.
' rnAbs were used at a final dilution of 1 :200 of ascites fluid.
Percent inhibition of proliferation.
3 Significant inhibitions are underscored.
II Proliferative response in the absence of mAbs (cpm x 10 -3).
second transplant (HLA-DR3,9) both recognized TT presented in the context of
HLA-DR4 or HLA-DR5 determinants of the recipient cells.
The T Cell Clones Restricted by the MHC ofthe Recipient Do not Recognize TT in the
Context ofDonor MHC To exclude that the recognition of the Ag in the context
ofallo HLA determinants ofthe recipient by the TT-specific T cell clones was due
to a crossreactivity between donorand recipient HLA determinants or to unknown
HLA molecules shared between the two cell populations, we tested the ability of
Tcellclones ofdonororigin to recognize TT inthe context ofselfHLA determinants.
SinceB cells andmonocytes ofdonororigin werenot available, weused an HTLV1-
transformed T cell clone (B21 p19) originated from the patient's PBL as APC. We
recently showed thatHTLV1-transformed TTspecific T cell clones can process and
present the Ag in an MHC-restricted fashion (Yssel, H., R. de Waal Malefyt, M.
Duc Dodon, D. Blanchard, L. Gazzolo, J. E. De Vries, and H. Spits, submitted
for publication). Therefore, we used this T cell clone, which is HLA identical with
the TTspecific T cell clones F9, F15, and F17, to test the proliferative response to
Ag in an autologous system.
As shown in Table VI, the T cell clones F9, F15, and F17 (HLA-DR3,9) recog-
nized TTpresented by SPS, but did not recognize the TT processed and presented
by the T cell clone B21 p19, which shares the same HLA-DR3,9 determinants. In
addition, they did not recognize TT presented by a second HTLV1-transformed
TTspecific T cell clone (827 p19), which was obtained from a normal donor and
which shares theHLA-DR3 molecule. In contrast, B21 p19, as well as827 p19, were
able to present the TT to the nontransformed T cell clone 827, which is restricted
by HLA-DR3. These responses were significant although lower thanthoseobtained
when the autologous EBV cell line HSY was used as AM In the absence ofTT
or APC, no proliferation ofthe T cell clones was observed.
AnalysisofMHCNonrestricted TT-specific TCellClones.
￿
As already shown in Table
III, the T cell clones Fl, F3, and F14 proliferate to TT in the presence ofboth pa-
tient's and parents' fresh PBL. To determine the restriction element recognized by
these clones, a study with a limited panel of EBV cell lines was performed. In Fig.
1, itis shown that clone F1 responded to TT when EBV cell lines sharingthe HLA-
mAb added` F9 F11
Responder T cell
F13
clones
F15
W6/32 (anti-HLA-A, B, C) 0 0 11 0
SPV-L3 (anti-HLA-DQ) 0 0 0 0
135 (anti-HLA-DR) _75§ 85 86 90
Q5/13 (anti-HLA-DP, DR) 56 99 95 982146
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TABLE VI
Proliferative Response ofHLA Class II-restricted T Cell Clones to TT
Presented by HTLV-1-infected T Cell Clone B21p19
In all cases, the SD was <10% of total cpm and no [3H]TdR incorporation
was observed in the absence of TT .
t [3H]TdR incorporation . Significant [3H]TdR incorporation is underscored .
DR4 with the recipient were used . In addition, positive responses were observed
with TT plus EBV cell lines bearing the HLA-DR1 antigen . These data indicate
that the TT response of the clone F1 is restricted by HLA-DR4 and suggest a pos-
sible crossreactivitybetween theHLA-DR4andHLA-DRI molecules, whichwould
explain why this clone reacted with both the cells of the father (HLA-DR4,7) and
the mother (HLA-DR1,5) .
Clones F3 and F14 were able to recognize TT presented by any EBV cell line
tested, irrespective of theirHLA phenotype (Fig . 1) . Theproliferative responses could
also be induced by the EBV cell lines pulsed with TT for 18 h and subsequently
washed (not shown), suggesting that these T cell clones recognized processed TT
proteins on the surface ofEBV cell lines with different HLA phenotypes . It could,
however, not be excluded that the T cell clones recognize native TT just stuck to
the membranes of the allogeneic EBV cell lines . To clarify this point, APC were
pulsed with TT in the presence or absence of chloroquine, which inhibits intracel-
lularAg processing, and then fixed with glutaraldehyde to prevent any further pro-
cessing. In Table VII, it is shown that theEBV cell line SPS pulsed with TT and
FIGURE 1 . Proliferative re-
sponse ofHLA; nonrestrictedT
cell clones to TT presented by
apanel ofEBV cell lines. Solid
bars, hatched bars, and grey
bars represent [3H]TdR incor-
poration (cpm x 10-3 ) of theT
cell clones Fl, F3, and F14,
respectively.T cell clone F3 was
not tested with UD61 as APC.
In all cases, the responses ofT
cells in the presence of TT or
APO alone was <103 cpm and
the SD was <10% .
APO
HLA-DR
phenotype
F9
(DR 3,9)
ResponderT cell clones'
F15 F17
(DR 3,9) (DR 3,9)
827
(DR 3,7)
cpm x 10 - -3
SPS 4.5 51 .31 36 .8 82.8 0 .1
HSY 3 .7 0.1 0 .1 0.6 38 .6
B21p19 3.9 0 0.1 0.1 13 .2
827p19 3.7 0 0.6 0 23 .8RONCAROLO ET AL.
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TABLE VII
HLA Nonrestricted T Cell Clones Recognize Processed Antigen
" The host-derived EBV cell line SPS was used as APC.
t In all cases, the SD was <10% of the total cpm.
S F17 recognizes TT in the context of HLA-DR5.
II [3H]TdR incorporation .
then fixed with glutaraldehyde can present Agto the T cell clones F3, F14, and F17.
The addition of chloroquine during the Ag pulse resulted in strong reduction of
proliferationofT cellclones F3 and F14. This inhibitionwas similarto thatobserved
with the TTspecific T cell clone F17, which is HLA-DR5 restricted. These data
indicate that the broadly reactive clones F3 and F14 recognize a processed TT pro-
tein on the surface of EBV cell lines.
To determine whether TT was recognized in the context ofMHC determinants
by these Tcell clones, blocking studies with mAbs directed against class I and II
HLA antigens were performed. Proliferation ofclones Fl and F14 was significantly
inhibited by mAbs 135 and Q5/13, which are specific for the class II HLA deter-
minants. In contrast, the response ofclone F3 wasnot inhibited by any ofthe mAbs
tested (Table VIII).
Discussion
We studied apatient suffering from SCIDwho was successfully transplanted with
two subsequent HLA-mismatched FLTT >10 yr ago. In this child, we observed a
TABLE VIII
The Effect of Anti-HLA mAbs on the Proliferative Response of
TT-specific HLA Nonrestricted T Cell Clones
79.3 t 3 .80 ￿48 .5 t 0.911
The host-derived EBV cell line SPS was used as APC .
" mAbs were used at a final dilution of 1 :200 of ascites fluid.
t Percent inhibition of proliferation.
S Significant inhibitions are underscored.
II Proliferative response in the absence of mAbs (cpm x 10
12.5 t 0.211
mAb added` Fl
Responder T cell
F3
clones
F14
W6/32 (anti-HLA-A,B,C) 19t 0 0
SPV-L3 (anti-HLA-DQ) 0 0 0
135 (anti-HLA-DR) 495 0 47
Q5/13 (anti-HLA-DP, DR) 62 0 70
Treatment of APC
before fixation" F3
Responder T cell clonest
F14
cpm x 10-3
F17S
- 011 0.1 0.5
TT 1:400 26.0 8.9 24.4
TT 1:1,000 20.7 10.2 25.9
Chloroquine + TT 1 :400 2 .7 2.6 14.5
Chloroquine + TT 1 :1,000 0.2 0.5 5.72148
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stable engraftment of T cells from the second transplant while the cells from the
firsttransplant, initially present, progressively disappeared and eventually were not
readily detectable in the peripheral blood. The B cells and monocytes remained of
host origin. Despite this situation ofsplit chimerism, the patient was able to mount
normal in vivo antibody responses against thymus-dependent antigens such as TT
(9, 10). In addition, TTspecific proliferative and antibody responses were observed
in vitro (11). These data indicated that full immunological reconstitution could be
achieved also when thetransplanted cellsare completely mismatched with the recip-
ient and suggested a possible cooperation between donor-derived T cells and host
cells across the allogeneic barrier.
It wasthereforeimportant todissect thisT cell-APC interactionatthe clonal level,
and for this reason, TTspecific T cell clones were generated from patient's PBL.
Results shown inthe present paperclearlydemonstratethatAg-specific T cellclones
ofdonor origin were able to recognize TT in association with class II MHC deter-
minants expressed by the recipient APC. Interestingly, HLA typing performed at
the clonal level revealed that a proportion ofthese TTspecific T cell clones, which
were able to proliferate toTT presented bythe recipientcells, have the HLA pheno-
type ofthe first donor. This finding indicates that, in spite of the fact that T cells
from the first transplant were not readily detectable in PBL by conventional HLA
typing, these cells are still circulating and can become functional. The specificity
of this Ag recognition in the context ofhost MHC Ags was clearly demonstrated
by the observation that the T cell clones Fl, F9, Ell, F13, F15, and F17 proliferated
in response to TT presented not only bythe EBV cell line ofthe recipient, but also
by the EBV cell lines of the parents and by allogeneic EBV cell lines sharing the
relevant HLA antigens. The blocking experiments with mAbs specific for class I
or class II HLA molecules confirmed that TT is recognized in the context ofclass
II HLA. T cell clones F9, F15, and F17, which originated from the fetal cells ofthe
second transplant, recognized Ag in the context of HLA-DR5; while HLA-DR4
was the restriction element ofT cell clones Fl, F11, and F13, the latter two were de-
rived from the first donor.
Thepositive responsestoTTobtainedwhen freshPBL ofthe patient and his parents
were used as APC suggest that theAgrecognition observed in vitro reflects a system
operational in vivo and is not related to the use ofEBV cell lines as APC. Further-
more, the demonstration that these T cell clones are not able to proliferate to TT
presented by self APC indicates that the Ag recognition in the context of the allo
MHC observed in this patient is not due to a crossreactivity between the HLA de-
terminants o£ the recipient and the transplanted T cells or to the presence of
unidentified HLA molecules shared between the recipient and the donors. From
these findings, it canbe concludedthatin thishuman chimera, there are twodifferent
populations ofmature T cells (one, HLA-DR3,9, and the other, HLA-DR1,8) that
have the capacity to recognize Agin the contextofHLA-DR5 and HLA-DR4 deter-
minants of the recipient and do not recognize the Ag in the context of self.
These datademonstrate thatrecipient and donorcellsbearingdifferentHLApheno-
types cooperate across the allogeneic barrier and refute the hypothesis that in such
cases interactions ofT lymphocytes with cells ofthe HLA-mismatched hosts would
be low or absent (19). Furthermore, our results can explain why transplantation of
fully allogeneic stem cells results in the development ofnormal immune responsesRONCAROLO ET AL.
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even when a split chimerism is established. In addition, they indicate that HLA-
restricted T cellrecognition ofThelper cellsin human chimeras is adoptively gener-
ated underthe influenceofenvironmental MHC, rather than beingdependentfrom
the genotypeofstem cells. Our dataare in line with thoseobtainedin murine lympho-
haemopoietic chimeras (4, 5, 20, 21). In these chimeric animals, the thymus plays
acentralrolein the educationprocess, andthe MHC phenotype ofthethymus seems
to determine the selection ofthe T cell repertoire (2, 6). In particular it has been
recently shown that the MHC molecules expressed on the thymic epithelial cells
specifically dictate the pattern of MHC restriction, while the MHC antigens ex-
pressed on the bone marrow-derived cells control the induction oftolerance (22).
Results obtained in transplanted SLID mice also demonstratethat thebone marrow
pro-T cells ofdonor origin could colonize and differentiate in the host thymus (23).
In this patient, it is not clear whether the acquisition of Ag recognition in the
context ofalloMHC determinants ofthe recipient is the result ofan education pro-
cess oftransplanted fetal cells in the host thymus. In fact, in SCID children, data
about repopulation ofhost thymus by the transplanted Tcells are still fragmentary
andcontroversial (24-27). Several reports indicatethat transplanted T cellscolonize
the host thymus and suggest that immunoreconstitution has inductive or trophic
effects on thymic development (24, 25). On the other hand, observations in an im-
munologically reconstituted SCID patient who died from an unrelated cause after
transplantation showed little or no evidence of intrathymic differentiation of lym-
phocytes, while lymphocyte colonization and germinal center formation in periph-
eral lymphoid tissueswasobserved, suggesting an important roleofextrathymic sites
in the process ofT cell education in selfrecognition (27). In addition, the observa-
tion that a SCID patient was successfully treated by transfusion of PBL from a
histocompatible donor demonstrates that host thymic education is not a prerequi-
site to obtain a stable long-term immunological reconstitution (28).
We also isolated TTspecific T cell clones (F3 and F14) that are able to recognize
processed Ag presented by a panel ofallogeneic EBV cell lines irrespective oftheir
HLA phenotype. The Ag-specific proliferative response ofoneofthese clones could
be blocked bythe anti-class II mAbs indicatingthat it recognized Agin the context
of class 11 HLA molecules. Whether these MHC nonrestricted TTspecific T cell
clones represent an alternative mechanism of Ag responsiveness developed during
the differentiation ofthe fetal cells in an MHC-mismatched environment, or whether
they result from anabnormal or incomplete thymic education, remains to be deter-
mined. It is interesting to note that both these MHC nonrestricted T cell clones
have the HLA phenotype ofthe first transplant. The significance of this finding is
presently unclear.
We recently demonstrated that no or incomplete clonal deletion ofhost-reactive
T cells from the repertoire took place(18). In fact, a series ofcytotoxic and prolifera-
tive T cell clones specific for the recipient cells has been isolated in vitro from pa-
tient's PBL. These clones were either CD8+ and directed against class I MHC an-
tigens, or CD4+ and specific for class II MHC antigens (18). Therefore, this patient
possesses precursors ofhost-reactive proliferative/cytotoxic effector cells and also pre-
cursors ofeffector cells capable ofgenerating host-restricted antigen-specific responses.
These findings underscore the fact that the mechanisms for deletion ofself-reactive
clones and the generation ofMHC-restricted response are different. A recent hy-2150
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pothesisputforward by Marrack et al. (22) predicts that self-reactive clones are elim-
inated in the host thymus when they come in contact with bone marrow-derived
APCofrecipientorigin. Sinceprecursors ofself-reactingclones were not eliminated
in this patient, ourdata imply that either the transplants matured in a host thymic
environment that contained onlyhost thymic epithelial cellsand nobonemarrow-de-
rived cells or that antigen-specific MHC-restricted precursors are not educated in
the thymus (29).
Finally, it has to be mentioned that in this patient the mechanism(s) responsible
for the induction and maintenance of tolerance ofthe T cells derived from the two
transplants towards each other and towards the non-T cells of the host remain un-
known, but suggest the presence of important suppressor mechanisms.
Summary
Tetanus toxin (TT)-specific T cell clones of donor origin were obtained from a
patient with severe combined immunodeficiency (SLID) successfully reconstituted
bytransplantationofallogeneic fetal liverandthymus cells from two different donors
performed 10 yr ago. A series ofthese clones recognized TT in the context of"alld"
class II HLA determinants expressed by recipient APC. The restriction element
oftwo T cell clones with the HLA phenotype ofthe first donor (HLA-DR1,8) and
one T cell clone with the HLA phenotype ofthe second transplant (HLA-DR3,9)
was HLA-DR4ofthe recipient, whereas other Tcell clones derivedfrom the second
transplant recognized TT in thecontext ofHLA-DR5 oftherecipient'sAPC. These
latter T cell clones were not able to proliferate in response to TT when autologous
APC were used. Thesedatademonstratethat recipient and donorcellshaving different
HLA phenotypes could cooperate across the allogeneic barrier and that MHC re-
striction ofantigen(Ag) recognitionis independent from the MHC genotype ofthe
T cells but is influenced by the environment in which the T cells mature.
We also isolated T cell clones thatwere abletorecognize processed TT presented
by all allogeneic EBVcell lines tested, indicatingthat theAgspecificityoftheseclones
was not restricted by aparticularclass II MHC molecule. The Ag-specificprolifera-
tive response ofone of these clones could be blocked by anti-class II MHC mAbs.
These results demonstratethatin addition toAgrecognitionin thecontext ofspecific
class II MHC Ags, other types ofAg-specific responses may occur in this human
chimera. It is not clear whetherthis"allo"plus Ag recognition is the result ofeduca-
tion of transplanted fetal cells in the host thymus. Taking into consideration our
previous findings indicating that alloreactive T cell clones specific for the recipient
cells could be isolated in vitro from the PBL of the same patient, our data suggest
that the mechanism for deletion ofself-reactive clones andthe generation ofMHC-
restricted responses are different.
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